08:47 AM EST, 02/04/2025 (MT Newswires) -- Zoetis ( ZTS ) said Tuesday that it has updated the US label for Librela following its submission of a supplement to the US Food and Drug Administration based on post-approval experiences with the veterinary drug.

The company said it remains confident in the safety and effectiveness of the treatment for the pain associated with osteoarthritis in dogs.

The company said that out of 25 million doses, no adverse event has been reported at a rate higher than rare, representing less than 10 occurrences per 10,000 treated dogs.

Shares of the company were down more than 1% in Tuesday's premarket activity.